These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23011763)

  • 41. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck.
    Cheng L; Sturgis EM; Eicher SA; Spitz MR; Wei Q
    Cancer; 2002 Jan; 94(2):393-7. PubMed ID: 11900225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.
    Ang MK; Patel MR; Yin XY; Sundaram S; Fritchie K; Zhao N; Liu Y; Freemerman AJ; Wilkerson MD; Walter V; Weissler MC; Shockley WW; Couch ME; Zanation AM; Hackman T; Chera BS; Harris SL; Miller CR; Thorne LB; Hayward MC; Funkhouser WK; Olshan AF; Shores CG; Makowski L; Hayes DN
    Clin Cancer Res; 2011 Oct; 17(20):6542-52. PubMed ID: 21908577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.
    Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV
    Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of histological typing in nasopharyngeal carcinoma.
    Cheung F; Chan O; Ng WT; Chan L; Lee A; Pang SW
    Oral Oncol; 2012 May; 48(5):429-33. PubMed ID: 22177891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
    El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
    J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy.
    Camacho M; Piñeiro Z; Alcolea S; García J; Balart J; Terra X; Avilés-Jurado FX; Soler M; Quer M; León X; Vila L
    J Pathol; 2015 Jan; 235(1):125-35. PubMed ID: 25256272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
    Li J; Li ZN; Yu LC; Bao QL; Wu JR; Shi SB; Li XQ
    Lung Cancer; 2010 Jul; 69(1):116-22. PubMed ID: 19875192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
    Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
    N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
    Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
    Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
    Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
    Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF; Deng SJ; Weng WW; Guo G; Chen N
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
    J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.